ICAD: Jumps on FDA nod for new version of mammography software

icad

16/03/2021 10:14

** Shares of medical-device manufacturer  ICAD.O  soar 20%
to $22.50 premarket
    ** Co said on Monday aftermarket U.S. FDA had cleared a new
version of its artificial intelligence software for 3-D
mammography or breast imaging  urn:newsml:reuters.com:*:nGNX1WFlrN
    ** ProFound AI Version 3.0 offers up to 10% improvement in
specificity performance and up to 1% improvement in sensitivity
- ICAD
    ** Sensitivity and specificity are measures of a test's
ability to correctly classify a person as having or not having a
disease
    ** The new version analyzes each image, detecting both
malignant soft tissue densities and calcifications
    ** Stock up ~42% this year, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))